CompanyGraph
Sells hospital sterilization systems and electrical test instruments that customers are legally costly to stop using.
- Depends onUpstream position: supplies 3 industries, depends on 0
- ScaleMarket cap is above the global median
- PositionCurrent ratio is lower than 95% of its Scientific & Technical Instruments peers
- Interpretations2 currently firing — 1 · 1
What this company is and how it runs — written from structure, not news.
Fortive sells two types of products — Sterrad sterilization systems to hospitals and Fluke electrical test instruments to industrial and pharmaceutical facilities — where the real business is not the hardware but the regulatory procedures built around it. A hospital running Sterrad cannot swap in a competing hydrogen peroxide cartridge because the FDA cleared the sterilization cycle as a single closed system — chamber geometry, plasma parameters, and that specific consumable formulation together — so any substitution triggers a months-long revalidation of every surgical instrument the hospital sterilizes. On the Fluke side, once a specific instrument model is written into a calibration procedure that a regulator has already reviewed, replacing it means formally requalifying the measurement method, not just ordering different hardware. Both businesses can add customers in new regions, but Fluke's expansion is gated by how quickly Fortive can build ISO 17025 accredited, temperature-controlled metrology laboratories staffed with certified technicians — without that infrastructure, customers in a new market cannot legally close the compliance loop and the instruments have no regulated use.
How does this company make money?
The company earns money in three ways. First, it sells Fluke electrical instruments and Sterrad sterilization systems as hardware — each unit sold generates a one-time payment. Second, and more steadily, hospitals must buy Sterrad hydrogen peroxide consumable cartridges every time they run a sterilization cycle, so each installed Sterrad system generates ongoing cartridge purchases tied directly to operating room activity. Third, Fluke customers pay for calibration services either on an annual contract or each time a service event occurs, because regulators require periodic recalibration to keep the instruments valid for compliance use.
What makes this company hard to replace?
A hospital that wants to move away from Sterrad must revalidate its entire sterile processing program — every instrument category, every cycle parameter — because the FDA cleared the existing process as a single closed system including the specific hydrogen peroxide formulation. That revalidation takes months and disrupts operating room throughput while it is underway. On the Fluke side, once a specific instrument model is written into a calibration procedure or a pharmaceutical process validation protocol that a regulator has already reviewed, changing to a different brand means requalifying the measurement method with that regulatory body, which is a formal process — not a simple equipment swap.
What limits this company?
Fluke can manufacture instruments relatively quickly, but it cannot serve a new country or region until there is a temperature-controlled, ISO 17025 accredited calibration laboratory in that area staffed with certified technicians. Without that laboratory, customers in that region cannot get the NIST-traceable recalibration their regulators require. Building that infrastructure takes time and money in every new market, and that requirement — not how fast instruments can be made — is what slows geographic expansion.
What does this company depend on?
The company cannot operate without NIST-traceable reference standards for calibrating Fluke instruments, FDA 510(k) clearances that authorize Sterrad sterilization systems to be used in hospitals, a functioning supply chain for the proprietary hydrogen peroxide concentrate that powers Sterrad consumables, ISO 17025 accredited calibration laboratories that perform recalibration services, and semiconductor components that go into Fluke electrical measurement circuits.
Who depends on this company?
Hospital sterile processing departments rely on Sterrad systems to turn over surgical instruments between operations — without those systems running, operating room schedules would slow or stop. Electrical technicians in factories depend on Fluke instruments to meet OSHA electrical safety rules; without accurate Fluke readings, their compliance records fall apart. Pharmaceutical manufacturing facilities use calibrated Fluke instruments as part of the documentation required to release drug batches — if those instruments were gone, batch release would stall.
How does this company scale?
The software features and measurement algorithms inside Fluke instruments can be copied across new units at almost no extra cost per device. What does not scale cheaply is the calibration service network — every new geographic market needs its own certified, temperature-controlled metrology laboratory and trained technicians before customers in that region can legally use the instruments for regulated work.
What external forces can significantly affect this company?
FDA regulations requiring hospitals to validate their sterile processing programs drive when and how hospitals buy or upgrade Sterrad systems, so regulatory changes at the FDA directly affect demand cycles. OSHA electrical safety standards in industrial workplaces require calibrated test equipment, which sustains Fluke's installed base but also means any weakening of those standards could reduce urgency to recalibrate. Export control restrictions on advanced measurement technology limit which countries Fluke instruments can be sold into, capping international expansion in certain jurisdictions regardless of local demand.
Where is this company structurally vulnerable?
If the supply chain for the proprietary hydrogen peroxide concentrate cartridges failed and no alternative formulation existed within the existing FDA clearance, hospitals would have no legal path to substitute a different consumable — doing so would trigger complete sterile processing revalidation. The same regulatory lock-in that keeps hospitals from switching to a competitor would also prevent them from finding a quick workaround, halting sterilization capacity until a new FDA clearance could be obtained.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Near Multi-Tested High
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped advancing and pulled back, and (2) current price is back inside or just below that zone, near the top of its recent trading range. The retest is happening at a level the stock has reached before and turned away from.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
Buyback-to-OCF Elevated With Dividend Coverage-Stability Composite And 5-Year Buyback-to-Market-Cap Yield Elevated
Three capital-return observations have aligned: the most recent annual stock-repurchase outflow is large relative to operating cash flow, the dividend coverage-and-stability composite is elevated, and the 5-year average annual repurchase outflow is large relative to current market cap.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.